Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron

References

• NavariRMManagement of chemotherapy-induced nausea and vomitingDrugs20137324926223404093
   PubMed Web of Science ®Google Scholar
• GrunbergSMSlusherBRugoHSEmerging treatments in chemotherapy-induced nausea and vomitingClin Adv Hematol Oncol2013112 Suppl 111823598819
   PubMedGoogle Scholar
• RojasCSlusherBSPharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomitingEur J Pharmacol20126841–31722425650
   PubMed Web of Science ®Google Scholar
• PopovicMWarrDGDeangelisCEfficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trialsSupport Care Cancer20142261685169724590374
   PubMed Web of Science ®Google Scholar
• GaoHFLiangYZhouNNZhangDSWuHYAprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapyIntern Med J2013431737622141732
   PubMed Web of Science ®Google Scholar
• RojasCRajeMTsukamotoTSlusherBSMolecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesisEur J Pharmocol20147222637
   PubMed Web of Science ®Google Scholar
• AzizFNeurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomitingAnn Palliat Med20121213013625841473
   PubMedGoogle Scholar
• NavariRMRole of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trialsCancer Invest200422456957615565815
   PubMed Web of Science ®Google Scholar
• Di RenzoNMontaniniAManninaDSingle-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)Support Care Cancer2011191505151020694798
   PubMed Web of Science ®Google Scholar
• Product Monograph. Aloxi^®Missisauga, ONEisai Limited2012
   Google Scholar
• RojasCLiYZhangJThe antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivoJ Pharmacol Exp Ther2010335236236820724484
   PubMed Web of Science ®Google Scholar
• StoltzRCyongJCShahAParisiSPharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjectsJ Clin Pharmacol200444552053115102873
   PubMed Web of Science ®Google Scholar
• EisenbergPMackintoshFRRitchPCornettPAMacciocchiAEfficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical studyAnn Oncol200415233033714760130
   PubMed Web of Science ®Google Scholar
• IkariYOgataKNakashimaYSafety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapySupport Care Cancer20142271959196424590375
   PubMed Web of Science ®Google Scholar
• ShahADeGrootTApseloffGPharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjectsJ Clin Pharmacol200646101139114516988202
   PubMed Web of Science ®Google Scholar
• HuntTLGallagherSCCullenMTJrShahAKEvaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjectsJ Clin Pharmacol200545558959615831783
   PubMed Web of Science ®Google Scholar
• SadabaBdel BarrioACampaneroMARandomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapyPLoS One201492e8974724587006
   PubMed Web of Science ®Google Scholar
• HeskethPJMorrowGKomorowskiAWAhmedRCoxDEfficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)Support Care Cancer20122012633267722733373
   PubMedGoogle Scholar
• BocciaRGrunbergSFranco-GonzalesEEfficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trialSupport Care Cancer2013211453146023354552
   PubMed Web of Science ®Google Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronCancer200398112473248214635083
   PubMed Web of Science ®Google Scholar
• GrallaRLichinitserMVan Der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol200314101570157714504060
   PubMed Web of Science ®Google Scholar
• ChoiBSBorsaruGPBallinariGVoisinDDi RenzoNMulticenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapyLeuk Lymphoma201455354455023772665
   PubMed Web of Science ®Google Scholar
• MattiuzziGNCortesJEBlambleDADaily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemiaCancer2010116245659566621218459
   PubMed Web of Science ®Google Scholar
• DongXHuangJCaoRLiuLPalonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patientsMed Oncol2011281425142920602263
   PubMed Web of Science ®Google Scholar
• TianWWangZZhouJRandomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese populationMed Oncol201128717820049561
   PubMed Web of Science ®Google Scholar
• MaemondoMMasudaNSekineIA phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapyAnn Oncol200920111860186619561037
   PubMed Web of Science ®Google Scholar
• MassaEAstaraGMadedduCPalonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient responseCrit Rev Oncol Hematol2009701839118723369
   PubMed Web of Science ®Google Scholar
• AaproMFabiANolèFDouble-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnn Oncol20102151083108820080830
   PubMed Web of Science ®Google Scholar
• CelioLFrustaciSDenaroAPalonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupport Care Cancer20111981217122520574663
   PubMed Web of Science ®Google Scholar
• BrugnatelliSGattoniEGrassoDRossettiFPerroneTDanovaMSingle-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patientsTumori201197336236621789017
   PubMed Web of Science ®Google Scholar
• RozziANardoniCCoronaMPalonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II studySupport Care Cancer201119569770120467757
   PubMed Web of Science ®Google Scholar
• LorussoVGiampagliaMPetrucelliLSaracinoVPerroneTGnoniAAntiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapySupport Care Cancer201220123241324622534864
   PubMed Web of Science ®Google Scholar
• AogiKSakaiHYoshizawaHA phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapySupport Care Cancer20122071507151421808994
   PubMed Web of Science ®Google Scholar
• LorussoVSpedicatoAPetrucelliLSaracinoVGiampagliaMPerroneTSingle dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary resultsSupport Care Cancer200917121469147319294429
   PubMed Web of Science ®Google Scholar
• YavasCDoganUYavasGArazMAtaOYAcute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective studySupport Care Cancer201220102343234722170340
   PubMed Web of Science ®Google Scholar
• DoganUYavasGTekinalpMYavasCAtaOYOzdemirKEvaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarizationEur Rev Med Pharmacol Sci201216446246822696873
   PubMed Web of Science ®Google Scholar
• LongoFMansuetoGLapadulaVPalonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapySupport Care Cancer20111981159116420552375
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartmellAFergusonSGinkelACharuVCombination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitantJ Support Oncol20064840340817004515
   PubMedGoogle Scholar
• HeskethPJSanz-AltamiraPAprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomitingSupport Care Cancer201220365365622089429
   PubMed Web of Science ®Google Scholar
• GrunbergSMDuganMMussHEffectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapySupport Care Cancer200917558959419037667
   PubMed Web of Science ®Google Scholar
• KimKILeeDEChoIEffectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapyAnn Pharmacother201246121637164423170032
   PubMed Web of Science ®Google Scholar
• AaproMRugoHRossiGA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnn Oncol20142571328133324603643
   PubMed Web of Science ®Google Scholar
• HeskethPJRossiGRizziGEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal studyAnn Oncol20142571340134624608196
   PubMed Web of Science ®Google Scholar